^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Head and Neck Cancer |
| Drug: | Akalux (cetuximab sarotalocan) (EGFR-targeted-dye conjugate) |
| Direction: | Sensitive |
Evidence:
Title:
Rakuten Medical Japan Announces Marketing Approval of Akalux® IV Infusion 250mg and BioBlade® Laser System from the Ministry of Labour, Health and Welfare in Japan for Locoregional Cancer Treatment
Published date:
09/26/2020
Excerpt:
...Rakuten Medical Inc. is proud to announce that its wholly owned subsidiary Rakuten Medical Japan K.K. has received marketing approval in Japan from the Ministry of Health, Labour and Welfare for Akalux IV Infusion 250mg (cetuximab saratolacan sodium) to treat unresectable locally advanced or recurrent head and neck cancer.
